What top creators are saying about iShares Biotechnology ETF(IBB)

The chart was viewed as strong, and the speaker remained constructive provided the ETF held above approximately $199 on a weekly closing basis.

The speaker added to and continued to hold the ETF, preferring sector exposure over selecting individual biotech companies.

Reported up about 2% in a market snapshot, without a broader outlook.

IBB was mentioned in the market rundown, without specific commentary or a recommendation.

The host identified IBB as a healthcare ETF he held or favored and said healthcare funds had been among the stronger recent performers. He was not adding because the fund had not reached his preferred buying level.

The ETF was holding up better than many stocks during the selloff, indicating relative strength rather than guaranteed downside protection.

The host described IBB's chart as strong and noted frequent market discussion of biotech. The commentary was broadly constructive but did not provide a specific price target or detailed fund analysis.

The host was bullish, with a weekly close above $213 supporting a breakout and a close below roughly $197 prompting reconsideration.

The host called biotechnology one of his best current ideas and pointed to a strong-looking chart in IBB, citing growing interest in AI-enabled drug discovery.

The host said he owned the ETF and was long-term constructive, but a close below roughly $195 could signal a deeper pullback.

Consolidation near highs was viewed as constructive, with a bullish outlook above $185.

Mentioned without a specific investment case or recommendation.

Gained 3.5% to 4% as positive cancer trial news triggered a broad capital rotation into biotech stocks.

Rose nearly 5% as oncology breakthroughs drove a broad sector rotation from semiconductor and AI equities into healthcare.

Included in long positions alongside LLY

Benefiting from sector rotation out of tech, showing a fresh macro breakout; look for entries on weekly pullbacks.

Described as a 'sick trade' that is currently outperforming the broader technology market.

Identified as a breakout buy with strong upward momentum independent of sector leaders.

Showing a 'clean breakout' on technical charts, signaling a bullish trend for the sector.

Breaking out of a 2000-day consolidation; viewed as an AI high-beta play.

Identified as a way for investors to research and invest in the biotechnology sector, which is set to benefit from the government's 'Genesis Mission' to accelerate innovation using AI.